BrainStorm to Provide Corporate Update at the BIO International Convention

HACKENSACK, N.J. and PETACH TIKVAH, Israel, June 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in San Diego, California.

Presentation Details

Date:           Wednesday, June 21
Time:           2:00pm Pacific Time
Presenter:   Chaim Lebovits, Chief Executive Officer, BrainStorm Cell Therapeutics
Location:     San Diego Convention Center, Company Presentation Theater 3
Webcast:    http://www.veracast.com/webcasts/bio/internationalconvention2017/96236165162.cfm

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult mesenchymal stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS

Media:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-to-provide-corporate-update-at-the-bio-international-convention-300473770.html

SOURCE BrainStorm Cell Therapeutics Inc.